A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis
Status:
Recruiting
Trial end date:
2023-12-10
Target enrollment:
Participant gender:
Summary
This is a multi-center, prospective, single-arm study to assess safety and efficacy of
Ruxolitinib in myelofibrosis (MF) based on a new prognostic stratification.